NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Price, News & Analysis $1.15 -0.02 (-1.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.13▼$1.2050-Day Range$1.05▼$2.1052-Week Range$1.04▼$10.43Volume259,142 shsAverage Volume1.01 million shsMarket Capitalization$43.16 millionP/E RatioN/ADividend YieldN/APrice Target$11.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BioXcel Therapeutics alerts: Email Address BioXcel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside926.1% Upside$11.80 Price TargetShort InterestHealthy1.67% of Shares Sold ShortDividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews Sentiment0.72Based on 3 Articles This WeekInsider TradingSelling Shares$208,610 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.74) to ($1.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.55 out of 5 starsMedical Sector117th out of 936 stocksPharmaceutical Preparations Industry41st out of 436 stocks 3.3 Analyst's Opinion Consensus RatingBioXcel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageBioXcel Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about BioXcel Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.67% of the outstanding shares of BioXcel Therapeutics have been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 61.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for BioXcel Therapeutics is -1.13. Previous Next 2.6 News and Social Media Coverage News SentimentBioXcel Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioXcel Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for BTAI on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days.MarketBeat Follows7 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,610.00 in company stock.Percentage Held by Insiders35.80% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.68% of the stock of BioXcel Therapeutics is held by institutions.Read more about BioXcel Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.74) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioXcel Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyNvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.To see Porter Stansberry's new AI prediction go here now. About BioXcel Therapeutics Stock (NASDAQ:BTAI)BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Read More BTAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTAI Stock News HeadlinesJuly 23, 2024 | americanbankingnews.comReviewing BioXcel Therapeutics (NASDAQ:BTAI) and Journey Medical (NASDAQ:DERM)July 16, 2024 | globenewswire.comBioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual FilmJuly 27, 2024 | Porter & Company (Ad)I’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.May 28, 2024 | globenewswire.comBioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceMay 21, 2024 | globenewswire.comBioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 14, 2024 | markets.businessinsider.comHold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial UncertaintiesMay 10, 2024 | markets.businessinsider.comBullish Outlook: Bioxcel Therapeutics’ Revenue Surge and Promising Clinical Trials Fuel Buy RatingMay 10, 2024 | finance.yahoo.comBioXcel Therapeutics First Quarter 2024 Earnings: Misses ExpectationsJuly 27, 2024 | Porter & Company (Ad)I’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.May 10, 2024 | finance.yahoo.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 BioXcel Therapeutics Inc Earnings CallMay 9, 2024 | investorplace.comBTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | msn.comBioXcel Therapeutics GAAP EPS of -$0.87 misses by $0.12, revenue of $0.58M misses by $0.05MMay 9, 2024 | globenewswire.comBioXcel Therapeutics Reports First Quarter 2024 Financial ResultsMay 8, 2024 | msn.comBioXcel Therapeutics Q1 2024 Earnings PreviewMay 1, 2024 | msn.com2 Contracts Traded for 20JUN24 BTI PHY DN Single Stock Dividend Neutral FutureApril 26, 2024 | markets.businessinsider.comHold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial UncertaintiesApril 25, 2024 | globenewswire.comBioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024See More Headlines Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTAI CUSIPN/A CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees90Year Founded2017Price Target and Rating Average Stock Price Target$11.80 High Stock Price Target$31.00 Low Stock Price Target$4.00 Potential Upside/Downside+926.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,050,000.00 Net Margins-8,715.72% Pretax Margin-8,715.72% Return on EquityN/A Return on Assets-154.37% Debt Debt-to-Equity RatioN/A Current Ratio2.57 Quick Ratio2.49 Sales & Book Value Annual Sales$1.38 million Price / Sales31.28 Cash FlowN/A Price / Cash FlowN/A Book Value($1.89) per share Price / Book-0.61Miscellaneous Outstanding Shares37,530,000Free Float24,095,000Market Cap$43.16 million OptionableOptionable Beta0.32 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Vimal D. Mehta Ph.D. (Age 62)Founder, CEO, President, & Director Comp: $1.76MMr. Javier Rodriguez (Age 51)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $638.88kMr. Matthew Wiley (Age 51)Senior VP & Chief Commercial Officer Comp: $620.12kMr. Richard I. Steinhart MBA (Age 67)Senior VP & CFO Comp: $404kDr. Frank D. Yocca Ph.D. (Age 67)Senior VP & Chief Scientific Officer Comp: $452.58kDr. Vincent J. O'Neill B.Sc. (Age 55)M.D., M.R.C.P., Executive VP and Chief of Product Development & Medical Officer Comp: $510.17kDr. Chetan D. Lathia Ph.D.Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory AffairsDr. Robert Risinger M.D.Chief Medical Officer - NeuroscienceMore ExecutivesKey CompetitorsSeres TherapeuticsNASDAQ:MCRBLifecore BiomedicalNASDAQ:LFCRSkye BioscienceNASDAQ:SKYERepare TherapeuticsNASDAQ:RPTXKodiak SciencesNASDAQ:KODView All CompetitorsInsiders & InstitutionsRosalind Advisors Inc.Bought 39,672 shares on 7/12/2024Ownership: 0.106%Vimal MehtaSold 2,134 sharesTotal: $2,731.52 ($1.28/share)Frank YoccaSold 372 sharesTotal: $476.16 ($1.28/share)Vimal MehtaSold 126,014 sharesTotal: $205,402.82 ($1.63/share)Virtu Financial LLCSold 45,524 shares on 5/20/2024Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions BTAI Stock Analysis - Frequently Asked Questions How have BTAI shares performed this year? BioXcel Therapeutics' stock was trading at $2.95 at the beginning of 2024. Since then, BTAI stock has decreased by 61.0% and is now trading at $1.15. View the best growth stocks for 2024 here. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.19. The company had revenue of $0.58 million for the quarter, compared to analyst estimates of $0.42 million. When did BioXcel Therapeutics IPO? BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are BioXcel Therapeutics' major shareholders? BioXcel Therapeutics' top institutional shareholders include Rosalind Advisors Inc. (0.11%). Insiders that own company stock include Vimal Mehta, Frank Yocca, Vincent O'neill, Richard I Steinhart and Krishnan Nandabalan. View institutional ownership trends. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL) and Invitae (NVTA). This page (NASDAQ:BTAI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.